Update shared on 26 Oct 2025
Fair value Increased 6.39%Analysts have raised their price target for Tempus AI from $77.55 to $82.50, citing stronger confidence in revenue growth and profitability projections.
What's in the News
- Tempus AI and Whitehawk Therapeutics announced a multi-year collaboration to use Tempus' real-world dataset to advance biomarker-driven research and enhance oncology clinical trial design. (Collaboration Announcement)
- The U.S. FDA granted 510(k) clearance to Tempus AI's RNA-based xR IVD device, which supports drug development through advanced RNA sequencing and fusion detection. (FDA Clearance)
- Tempus AI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to provide diagnostics and contract research services for the ADAPT program, which targets personalized cancer therapies. (Contract Award)
- Tempus AI was added to the S&P TMI Index. (Index Inclusion)
- A class action lawsuit was filed against Tempus AI, alleging misrepresentation of contract values, business practices, and revenue prospects, following a report that led to a nearly 20% drop in share price. (Legal Proceedings)
Valuation Changes
- Consensus Analyst Price Target has risen from $77.55 to $82.50, reflecting increased analyst confidence.
- The discount rate has increased slightly, moving from 7.34% to 7.39%.
- Revenue growth projection has risen from 30.94% to 31.67%.
- The net profit margin estimate is up marginally from 12.73% to 12.76%.
- The future P/E ratio forecast has increased from 74.71x to 78.12x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.